Metformin for Type 2 Diabetes: How It Works, Who Should Take It, and What to Expect

Why Metformin Remains the Foundation of Type 2 Diabetes Treatment

Metformin has been used to treat type 2 diabetes for over 60 years. Despite an explosion of newer, more complex medications, it remains the most prescribed diabetes drug in the world and the first-line recommendation of every major diabetes guideline. Understanding why — and what metformin actually does — helps people with type 2 diabetes make informed decisions about their treatment.

How Metformin Works

Metformin works primarily by reducing the amount of glucose the liver releases into the bloodstream. In type 2 diabetes, the liver often produces glucose inappropriately even when blood sugar is already elevated — a process called hepatic glucose production. Metformin suppresses this via the activation of AMPK (AMP-activated protein kinase), a cellular energy-sensing enzyme that also improves insulin sensitivity in muscle and fat tissue.

Metformin does not stimulate insulin release, which is why — unlike sulfonylureas or insulin — it rarely causes hypoglycemia (low blood sugar) when used alone.

What Metformin Does and Doesn’t Do

Metformin does:

• Lower fasting blood glucose and HbA1c (typically by 1–1.5 percentage points)
• Reduce hepatic glucose output
• Improve insulin sensitivity in peripheral tissues
• Support modest weight loss or weight neutrality (it does not cause weight gain)
• Reduce cardiovascular risk — the landmark UKPDS trial showed metformin reduced diabetes-related death by 42% in overweight patients, a benefit not seen with other glucose-lowering agents at the time
• Potentially reduce the risk of several cancers and slow aging processes (under active investigation in the TAME trial)

Metformin does not:

• Stimulate insulin production (it is not an insulin secretagogue)
• Cause significant weight gain
• Cause hypoglycemia when used as monotherapy
• Protect the heart, kidneys, or cardiovascular system to the same degree as newer agents like GLP-1 agonists and SGLT-2 inhibitors in high-risk patients

Who Should Take Metformin?

The American Diabetes Association Standards of Care recommend metformin as the preferred initial medication for most people newly diagnosed with type 2 diabetes, unless there are contraindications or specific reasons to choose a different agent first (e.g., established cardiovascular disease or heart failure, where GLP-1 agonists or SGLT-2 inhibitors may take priority).

Metformin is also recommended by the ADA for people with prediabetes who are at high risk of progressing to type 2 diabetes (BMI ≥35, history of gestational diabetes, or rising HbA1c toward 6.5%), as a complement to lifestyle intervention.

Contraindications and When to Use Caution

Metformin is generally not recommended for people with:

• Significant kidney impairment (eGFR below 30 mL/min/1.73m² — used with caution between 30–45)
• Severe liver disease or alcohol use disorder (risk of lactic acidosis)
• Planned major surgery or iodinated contrast procedures (usually held temporarily)

People with kidney function in the borderline range (eGFR 30–60) should have their metformin dose reviewed and their kidney function monitored regularly.

Side Effects and How to Manage Them

Gastrointestinal side effects — nausea, diarrhea, stomach upset — are the most common reason people have difficulty with metformin, occurring in roughly 20–30% of users. Most can be minimized by:

• Starting at a low dose and increasing slowly over weeks
• Always taking metformin with food
• Switching to extended-release (XR) formulation, which is significantly better tolerated

Long-term metformin use depletes vitamin B12, which can cause peripheral neuropathy over years. Annual B12 monitoring is recommended for anyone on long-term metformin, and supplementation is appropriate when levels are low.

Metformin’s Emerging Potential Beyond Diabetes

Metformin is one of the most studied drugs in the world for indications beyond its original purpose. Current and emerging areas of investigation include potential reduction in cancer incidence (particularly colon, breast, and prostate cancer), cognitive decline prevention, cardiovascular protection in non-diabetic populations, and longevity/aging research through the TAME (Targeting Aging with Metformin) trial, which is one of the largest aging-focused clinical trials ever funded by the National Institute on Aging.

The Bottom Line

Metformin’s longevity as the cornerstone of type 2 diabetes treatment is not inertia — it reflects a genuinely strong evidence base for safety, efficacy, affordability, and cardiovascular benefit. For most people newly diagnosed with type 2 diabetes, it remains the right starting point. Newer agents like GLP-1 agonists and SGLT-2 inhibitors have earned important roles alongside metformin for patients with specific high-risk conditions, but for the broad population, this century-old drug continues to earn its place at the center of care.

This article is for informational purposes only and does not constitute medical advice. Please speak with a qualified healthcare provider about your personal health situation and medications.

Related Reading

• Best Treatment Options for Type 2 Diabetes
• New and Emerging Drug Therapies for Type 2 Diabetes
• Type 2 Diabetes: Symptoms, Causes, and Management

keithsurveys2@gmail.com

Keith Williams is the creator of ABCs of A1C, an educational resource focused on blood sugar control and Type 2 diabetes awareness. His work focuses on translating complex metabolic and diabetes research into practical lifestyle information that readers can understand and apply in daily life.

See Full Bio